(Q36244452)

13 August 2017

1 reference

title

Genetic aspects of drug disposition and therapeutics (English)

1 reference

13 August 2017

Genetic Aspects of Drug Disposition and Therapeutics (English)

1 reference

https://api.crossref.org/works/10.1002/J.1552-4604.1992.TB03814.X

15 October 2022

1 reference

https://api.crossref.org/works/10.1002/J.1552-4604.1992.TB03814.X

15 October 2022

author name string

R. J. Guttendorf

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1613119

15 October 2022

P. J. Wedlund

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1613119

15 October 2022

language of work or name

1 reference

1 February 1992

1 reference

full work available at URL

13 August 2017

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fj.1552-4604.1992.tb03814.x

1 reference

https://api.crossref.org/works/10.1002/J.1552-4604.1992.TB03814.X

http://onlinelibrary.wiley.com/wol1/doi/10.1002/j.1552-4604.1992.tb03814.x/fullpdf

15 October 2022

1 reference

https://api.crossref.org/works/10.1002/J.1552-4604.1992.TB03814.X

The Journal of Clinical Pharmacology

15 October 2022

published in

1 reference

13 August 2017

volume

32

1 reference

13 August 2017

issue

2

1 reference

13 August 2017

page(s)

107-117

1 reference

Defective oxidation of drugs: pharmacokinetic and therapeutic implications

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1992.TB03814.X

Genetically determined variability in acetylation and oxidation. Therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1992.TB03814.X

Recent developments in hepatic drug oxidation. Implications for clinical pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1992.TB03814.X

Genetic variation in the human hepatic cytochrome P-450 system

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1992.TB03814.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1992.TB03814.X

Genetically determined polymorphisms in drug oxidation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1992.TB03814.X

Genetic polymorphism of trimethylamine N-oxidation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1992.TB03814.X

Methyltransferase pharmacogenetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1992.TB03814.X

Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1992.TB03814.X

Why hypertensive patients vary in their response to oral debrisoquine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1992.TB03814.X

Polymorphic hydroxylation of Debrisoquine in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1992.TB03814.X

Defective N-oxidation of sparteine in man: A new pharmacogenetic defect

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1992.TB03814.X

Impaired oxidation of debrisoquine in patients with perhexiline neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1992.TB03814.X

Impaired oxidation of debrisoquine in patients with perhexiline liver injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1992.TB03814.X

Differential stereoselective metabolism of metoprolol in extensive and poor debrisoquin metabolizers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1992.TB03814.X

Pharmacokinetic and pharmacodynamic consequences of stereoselective drug metabolism in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1992.TB03814.X

Stereoselective disposition of flecainide in relation to the sparteine/debrisoquine metaboliser phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1992.TB03814.X

Debrisoquine oxidation phenotype and susceptibility to lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1992.TB03814.X

The distribution of debrisoquine metabolic phenotypes and implications for the suggested association with lung cancer risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1992.TB03814.X

Ecogenetics of Parkinson's disease: 4-hydroxylation of debrisoquine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1992.TB03814.X

Evidence for polymorphic oxidation of sparteine in Japanese subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1992.TB03814.X

Polymorphism of the 4-hydroxylation of debrisoquine in the San Bushmen of southern Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1992.TB03814.X

Mephenytoin hydroxylation deficiency: kinetics after repeated doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1992.TB03814.X

Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1992.TB03814.X

Effects of ketoconazole on the polymorphic 4-hydroxylations of S-mephenytoin and debrisoquine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1992.TB03814.X

Mephenytoin hydroxylation in the Cuna Amerindians of Panama

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1992.TB03814.X

Nifedipine: variability in its kinetics and metabolism in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1992.TB03814.X

Cyclosporine metabolism in human liver: identification of a cytochrome P-450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1992.TB03814.X

Pharmacokinetics of nifedipine slow release tablet in Mexican subjects: further evidence for an oxidation polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1992.TB03814.X

Evidence for an enzymatic defect in the 4-hydroxylation of debrisoquine by human liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1992.TB03814.X

Characterization of the common genetic defect in humans deficient in debrisoquine metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1992.TB03814.X

Mephenytoin hydroxylation polymorphism: characterization of the enzymatic deficiency in liver microsomes of poor metabolizers phenotyped in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1992.TB03814.X

Genetic polymorphism of human cytochrome P-450 (S)-mephenytoin 4-hydroxylase. Studies with human autoantibodies suggest a functionally altered cytochrome P-450 isozyme as cause of the genetic deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1992.TB03814.X

A simple test for acetylator phenotype using caffeine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1992.TB03814.X

Dextromethorphan and caffeine as probes for simultaneous determination of debrisoquin-oxidation and N-acetylation phenotypes in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1992.TB03814.X

Rapid screening for polymorphisms in dextromethorphan and mephenytoin metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1992.TB03814.X

Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolizers of debrisoquine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1992.TB03814.X

Commentary: drug metabolism and pharmacogenetics

21 January 2018

9

1 reference

https://api.crossref.org/works/10.1002/J.1552-4604.1992.TB03814.X

15 October 2022

Pharmacogenetics

10

1 reference

https://api.crossref.org/works/10.1002/J.1552-4604.1992.TB03814.X

S-methylation in motorneuron disease and Parkinson's disease

15 October 2022

15

1 reference

https://api.crossref.org/works/10.1002/J.1552-4604.1992.TB03814.X

A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.

15 October 2022

20

1 reference

https://api.crossref.org/works/10.1002/J.1552-4604.1992.TB03814.X

Hypotensive response to debrisoquine and hydroxylation phenotype

15 October 2022

22

1 reference

https://api.crossref.org/works/10.1002/J.1552-4604.1992.TB03814.X

Polymorphic metabolism of the beta-adrenoreceptor blocking drugs and its clinical relevance

15 October 2022

23

1 reference

https://api.crossref.org/works/10.1002/J.1552-4604.1992.TB03814.X

Oxidation of tricyclic antidepressant drugs, debrisoquine and 7-ethoxyresorufin, by human liver preparations

15 October 2022

24

1 reference

https://api.crossref.org/works/10.1002/J.1552-4604.1992.TB03814.X

Phenformin-induced lacticacidosis associated with impaired debrisoquine hydroxylation

15 October 2022

27

1 reference

https://api.crossref.org/works/10.1002/J.1552-4604.1992.TB03814.X

Influence of genetic polymorphism on the metabolism and disposition of encainide in man

15 October 2022

28

1 reference

https://api.crossref.org/works/10.1002/J.1552-4604.1992.TB03814.X

Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences

15 October 2022

29

1 reference

https://api.crossref.org/works/10.1002/J.1552-4604.1992.TB03814.X

Characterization of a common genetic defect of cytochrome P-450 function (debrisoquine-sparteine type polymorphism)--increased Michaelis is Constant (Km) and loss of stereoselectivity of bufuralol 1'-hydroxylation in poor metabolizers

15 October 2022

31

1 reference

https://api.crossref.org/works/10.1002/J.1552-4604.1992.TB03814.X

Stereo- and regioselectivity of hepatic oxidation in man--effect of the debrisoquine/sparteine phenotype on bufuralol hydroxylation

15 October 2022

34

1 reference

https://api.crossref.org/works/10.1002/J.1552-4604.1992.TB03814.X

A human cytochrome P-450 is recognized by anti-liver/kidney microsome antibodies in autoimmune chronic hepatitis

15 October 2022

36

1 reference

https://api.crossref.org/works/10.1002/J.1552-4604.1992.TB03814.X

Ethnic differences in drug metabolism

15 October 2022

39

1 reference

https://api.crossref.org/works/10.1002/J.1552-4604.1992.TB03814.X

Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism

15 October 2022

42

1 reference

https://api.crossref.org/works/10.1002/J.1552-4604.1992.TB03814.X

Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man

15 October 2022

43

1 reference

https://api.crossref.org/works/10.1002/J.1552-4604.1992.TB03814.X

Stereoselective mephobarbital hydroxylation cosegregates with mephenytoin hydroxylation

15 October 2022

47

1 reference

https://api.crossref.org/works/10.1002/J.1552-4604.1992.TB03814.X

Propranolol's metabolism is determined by both mephenytoin and debrisoquin hydroxylase activities

15 October 2022

49

1 reference

https://api.crossref.org/works/10.1002/J.1552-4604.1992.TB03814.X

Polymorphism in hydroxylation of mephenytoin and hexobarbital stereoisomers in relation to hepatic P-450 human-2

15 October 2022

52

1 reference

https://api.crossref.org/works/10.1002/J.1552-4604.1992.TB03814.X

In vitro inhibition studies of two isozymes of human liver cytochrome P-450. Mephenytoin p-hydroxylase and sparteine monooxygenase

15 October 2022

53

1 reference

https://api.crossref.org/works/10.1002/J.1552-4604.1992.TB03814.X

Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese versus mainland Chinese

15 October 2022

56

1 reference

https://api.crossref.org/works/10.1002/J.1552-4604.1992.TB03814.X

Single-dose quinidine treatment inhibits metoprolol oxidation in extensive metabolizers

15 October 2022

69

1 reference

https://api.crossref.org/works/10.1002/J.1552-4604.1992.TB03814.X

Clinical significance of the sparteine/debrisoquine oxidation polymorphism

15 October 2022

70

1 reference

https://api.crossref.org/works/10.1002/J.1552-4604.1992.TB03814.X

Polymorphic dextromethorphan metabolism: co-segregation of oxidative O-demethylation with debrisoquin hydroxylation

15 October 2022

72

1 reference

https://api.crossref.org/works/10.1002/J.1552-4604.1992.TB03814.X

S-mephenytoin hydroxylation phenotypes in a Swedish population determined after coadministration with debrisoquin

15 October 2022

75

1 reference

https://api.crossref.org/works/10.1002/J.1552-4604.1992.TB03814.X

Simplified phenotyping with dextromethorphan by thin-layer chromatography: application to clinical laboratory screening for deficiencies in oxidative drug metabolism

15 October 2022

77

1 reference

https://api.crossref.org/works/10.1002/J.1552-4604.1992.TB03814.X

Relevance of genetic polymorphism in drug metabolism in the development of new drugs

15 October 2022

85

1 reference

https://api.crossref.org/works/10.1002/J.1552-4604.1992.TB03814.X

15 October 2022

Identifiers

1 reference

13 August 2017

1 reference